Comparison 22. Erythropoietin stimulating agents versus placebo.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
22.1 Fatigue	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
22.1.1 Haemodialysis	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
22.2 Weakness	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
22.2.1 Haemodialysis	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
22.3 Energy	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
22.3.1 Haemodialysis	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
22.4 Death (any cause)	2		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
22.4.1 Haemodialysis	2	137	Risk Ratio (M‐H, Random, 95% CI)	0.17 [0.01, 4.15]
22.5 Cardiovascular death	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
22.5.1 Haemodialysis	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
22.6 Depression	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
22.6.1 Haemodialysis	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
22.7 Clotting of vascular access	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
22.7.1 Haemodialysis	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected